

15 October 2019

ASX Limited
20 Bridge Street
Sydney NSW 2000

ASX ANNOUNCEMENT

CLEANSING NOTICE UNDER ASIC CORPORATIONS (SHARE AND INTEREST PURCHASE PLANS) INSTRUMENT 2019/547

Cellmid Limited (ASX: CDY) (Company) refers to the announcement made on 14 October 2019 in respect of a placement and proposed share purchase plan (**SPP**).

The Company intends to undertake a SPP offer (**Offer**) pursuant to an SPP Offer Booklet dated 15 October 2019.

In accordance with subparagraph 7(f)(ii) of *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/457*, the Company advises that:

1. the Company will make offers to issue shares under a purchase plan without disclosure to investors under Part 6D.2 of the *Corporations Act 2001 (Cth) (Act)*;
2. this notice is being given in accordance with *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/457*;
3. as at the date of this notice:
 - a. the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act; and
 - b. there is no excluded information for the purposes of sections 708A(7) and 708A(8) of the Act.

End

Contact:

Maria Halasz, CEO
T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.